Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
HKG: 1801
Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis
China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug
Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both...
Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...
Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...
Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...
Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...
Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...